Key Dates

Related Announcements

• November 18, 2024 - Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed). See PAR-25-095
• November 18, 2024 - Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed). See PAR-25-096 
• November 12, 2024 - Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required). See PAR-25-167
• November 08, 2024 - Exploratory Grants in Cancer Control (R21 Clinical Trial Optional). See PA-25-253
• November 7, 2024 - Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional). See PA-25-172
• November 5, 2024 - Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional). See PAR-25-103
• November 5, 2024 - Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional). See PAR-25-104
• October 31, 2024 - Dissemination and Implementation Research in Health (DIRH)  (R21 Clinical Trial Optional). See PAR-25-143  
• October 30, 2024 - Dissemination and Implementation Research in Health (DIRH) (R01 Clinical Trial Optional). See PAR-25-144
• October 30, 2024 - Dissemination and Implementation Research in Health (DIRH) (R03 Clinical Trial Not Allowed). See PAR-25-233
• October 18, 2024 - NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional). See PAR-25-078
• December 14, 2022 - National Cancer Institute Program Project Applications (P01 Clinical Trial Optional). See PAR-23-059
• May 05, 2020 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed). See PA-20-185 

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to inform potential applicants of NCI’s interest in receiving applications focused on survivorship research for people living with advanced and metastatic cancers. 

Background

With improvements in treatment and supportive care, there are a growing number of individuals living longer with metastatic cancer or advanced cancer that is unlikely to be cured. The survivorship needs of this population likely differ from cancer survivors diagnosed with and treated for early-stage disease, as they often undergo complex treatment regimens and procedures, and have greater distress, issues with prognostic uncertainty, symptoms related to newer therapies, and substantial healthcare needs related to the often-longer trajectory of their illness. Many of the needs of this population of cancer survivors have not been systematically documented or effectively managed. Innovative healthcare delivery models, including tailored strategies to address symptoms and coordinate complex care, are necessary to improve quality of life and other patient outcomes. In May 2021, the NCI held a public meeting to gather interested researchers, clinicians, advocates, patients, and survivors to identify evidence gaps and opportunities pertaining to research focused on individuals living with advanced and metastatic cancers in five scientific areas: epidemiology and surveillance, symptom management, psychosocial issues, healthcare delivery, and health behaviors. Evidence gaps were identified in each scientific area. Though progress has been made in identifying the population, addressing these evidence gaps and other emerging challenges will improve the evidence base and inform strategies to optimize survival and survivorship for this understudied population. 

Research Objectives

The National Cancer Institute (NCI) is interested in applications proposing observational or intervention studies focused on survivorship for people living with advanced and metastatic cancers. Research interests include, but are not limited to, studies of:

• Clinical, genomic, and lifestyle factors associated with living longer with advanced or metastatic cancer
• Trajectories of physiological and psychological symptoms among people living with advanced or metastatic cancer
• Innovative models of health care delivery focused on the needs of people with advanced or metastatic cancer
• Prognostic awareness, uncertainty, and communication between providers, survivors, and caregivers
• Strategies to address care needs for people living with advanced and metastatic cancers from populations that experience health or care disparities

Applications may focus on cancer survivors diagnosed at any age (childhood through adulthood) and may focus on a single cancer type or multiple cancer types. Applicants must adequately describe the population proposed in the study, including a justification for how this is a population living with likely incurable cancer. NCI strongly encourages applicants to include a plan for survivor engagement during the development, planning, and conduct of the proposed research project. 

Application and Submission Information

This notice applies to Application Due Dates on or after February 5, 2025, and subsequent Application Due Dates through the expiration date of this NOSI (January 08, 2028).

Applicants are strongly advised to check/verify the Application Due Date matrix listed in each of the notices of funding opportunity (NOFOs) listed below before applying.

Submit applications using one of the following notices of funding opportunity (NOFO) or any reissuances of these announcements through the expiration date of this notice.

All instructions in the How to Apply - Application Guide and the notice of funding opportunity used for submission must be followed, with the following additions:

• For funding consideration, applicants must include “NOT-CA-25-024” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Applications nonresponsive to terms of this NOSI will be withdrawn from consideration for this initiative.

Inquiries

Please direct all inquiries to the contacts in Section VII of the listed notice of funding opportunity with the following additions/substitutions:

Scientific/Research Contact(s)

Michelle Mollica, Ph.D., M.P.H., R.N., O.C.N.
National Cancer Institute (NCI)
Telephone: 240-276-7621
Email:[email protected]

Lisa Gallicchio, Ph.D.
National Cancer Institute
Telephone: 240-276-5741
Email: [email protected]

Peer Review Contact(s)

Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).

Financial/Grants Management Contact(s)

Crystal Wolfrey
National Cancer Institute
Telephone: 240-276-6277
Email: [email protected]